Ascent Industries Co. (NASDAQ:ACNT) Q3 2023 Earnings Call Transcript

Ascent Industries Co. (NASDAQ:ACNT) Q3 2023 Earnings Call Transcript November 12, 2023

Operator: Good afternoon, everyone and thank you for participating in today’s Conference Call to discuss Ascent’s Financial Results for the Third Quarter ended September 30, 2023. Joining us today are Ascent’s Executive Chairman of the Board, Ben Rosenzweig; President and CEO, Chris Hutter; CFO, Bill Steckel; and the company’s outside Investor Relations Adviser, Cody Cree. [Operator Instructions] Before we go further, I would like to turn the call over to Cody Cree as he reads the company’s Safe Harbor statement within the meaning of the Private Securities Litigation Reform Act of 1995 that provides important cautions regarding forward-looking statements. Cody, please go ahead.

Cody Cree: Thanks, Sheri. Before we continue, I’d like to remind all participants that the discussion today may contain certain forward-looking statements pursuant to the Safe Harbor provisions of the federal securities laws. These statements are based on information currently available to us and are subject to various risks and uncertainties that could cause actual results to differ materially. Ascent advises all those listening to this call to review the latest 10-Q and 10-K posted on its website for a summary of these risks and uncertainties. Ascent does not undertake the responsibility to update any forward-looking statements. Further, the discussion today may include non-GAAP measures. In accordance with Regulation G, the company has reconciled these amounts back to the closest GAAP-based measurement.

The reconciliations can be found in the earnings press release issued earlier today and posted on the Investors section of the company’s website at ascentco.com. Please note that this call is available for replay via webcast link that is also posted on the Investors section of the company’s website. Additionally, an updated presentation is available on the Investor Relations section of the website which we encourage you to view. With that, I’d like to turn the call over to Ascent’s Executive Chairman of the Board, Ben Rosenzweig. Ben?

Ben Rosenzweig: Thank you, Cody and good afternoon, everyone. After a challenging last few quarters and the closing of our Munhall operations officially behind us, we began seeing signs of improvement within our operations during the third quarter. I want to be clear that we still do not view our current level of performance as acceptable and there is much work left to be done but we are turning the corner. Persistent volatility in the macro environment still hampered sales volumes across both segments in the third quarter as we continue to see larger-scale projects being pushed out or delayed, along with several of our end markets experiencing a decline in demand. Despite the lower sales volumes, we were able to return to positive adjusted EBITDA in the quarter and continued to manage working capital more efficiently.

Most impactfully, towards the end of the quarter, we were pleased to welcome Bryan Kitchen to Ascent as President of Ascent Chemicals. Bryan joins Ascent with a proven track record of taking underperforming businesses and putting them back on the road to growth and profit maximization. We believe Bryan has the potential to take Ascent Chemicals to new heights with a durable growth strategy and we are pleased with the actions he has already taken to return this segment to profitable growth. Within our tubular segment, we continue to streamline and optimize our operations now that we have completely shuttered our Munhall facility. While we do expect some cash and noncash costs within the ranges we laid out last call, we have worked through the vast majority of the expected costs and look forward to having this completely off our books as we enter 2024.

We continue to believe we have a healthy asset base and strong reputation within the tubular industry that can return to consistent growth and generate the earnings and cash flow to fund future growth opportunities. Similar to our specialty chemicals segment, our sales are continuing to be impacted by the broader economic slowdown. While some of our end markets have been more affected than others, particularly those for premium ornamental stainless steel tubing that go into more discretionary purchases, it is safe to say that we are seeing a heightened level of caution when it comes to spending across many of our distribution customers. We still believe there is healthy long-term demand potential for premium American-made tubular products and we’re continuing to optimize our operations to be ready for when the pendulum swings back in our favor.

In terms of capital allocation, our biggest priority has been and will continue to be repurchasing shares in the open market. In fact, we’ve repurchased nearly 100,000 shares in the open market through the first 9 months of 2023. We were able to ramp up our volumes significantly in Q3 with the 10b5 program in place, repurchasing nearly 45,000 shares which is almost 2.5x more than we were able to repurchase last quarter. Now that we can effectively repurchase stock in the open market nearly every single day, we continue to expect to be as aggressive as possible on this front. M&A does remain a long-term focus for our organization but we recognize the need to focus on building a more stable foundation prior to layering in larger deals. We are nowhere near satisfied with how this year has gone but I do believe that where we sit today and as we work through our budgeting process for 2024, we made it over the largest of our hurdles and the company is well positioned to be much more focused and efficient.

We continue to appreciate the patience of our shareholders and remained aligned with your interests as the largest holders of the company’s shares. We have unquestionably made mistakes but have learned from them and feel very confident in the team we’ve assembled to lead this company into 2024. We look forward to re-earning your trust over the coming quarters. Now, I’d like to pass the call over to Chris to provide more details on our operational performance in both segments. I’ll be back to answer any questions during the Q&A portion. Chris, over to you.

Chris Hutter: Thanks, Ben and thank you all for joining today’s call. Jumping right into our tubular products segment. We are pleased to be moving forward with our focus being squarely on Bristol tubular products, American stainless tubing and specialty pipe and tube now that operations have completely ceased at Munhall. During Q3, destocking trends within the industry continued to persist as many of our customers remained over-inventoried relative to their immediate needs. This is directly correlated with both the prolonged volatility we continue to experience in our broader macroeconomic economy and our distribution customers’ uncertainty surrounding near-term commodity pricing. Surcharges continue to work down, especially on a year-over-year basis which is not necessarily bad for us long term but certainly played a role in slowing inventory buys from distributors.

Though difficult to predict, we’d expect surcharges to come down a bit more throughout the end of the year with larger buys coming during periods of flattened surcharges. As we’ve discussed in the past, we’ve been targeting larger infrastructure projects for this segment that provide a healthier margin profile for us. Unfortunately, we have seen many of these orders pushed out 1 to 2 quarters which continue to be a drag in our volumes. However, we have a scrappy team that is turning over every stone to drum up demand and we are working hard to optimize factors within our control. Import products continue to impact volumes, specifically in our smaller-diameter products. However, we’re seeing some signs of stabilization and have begun to begin winning business back due to quality issues of the imported products.

We would expect this to continue to help us but some of it still depends on the health of the broader economy which ultimately impacts the price versus quality decisions of our customers. Within ASTI we’re holding relatively stable even with a meaningful drop in end market demand for some of the high-end consumer products we supply, specifically the marine market which is down over 40% year-over-year as consumers pare back these types of luxury purchases. But we have remained aggressive on pricing and believe we are beginning to take some market share here as we can afford a much more quick turn inventory model than our competitors which is valued highly during times of end market fluctuations. During the year, we embarked on some products that we believe would drive cost savings and avoidance at all facilities.

I’m pleased that those efforts accelerated further in Q3 with some vendor consolidation on the procurement side and the use of some of the excess equipment supplies from the closure of Munhall to be used across our remaining sites in place of purchasing new equipment. These are initiatives that not only are large in an individual basis but can aggregate in the 6 figures and help us control costs throughout all input pricing environments. We continue to have confidence in the long-term viability of our tubular products segment. We worked through down cycles before. So none of this is new to us but it’s obviously still challenging. The biggest difference is we no longer produce commodity galvanized product out of a high-cost facility like we were dealing with at Munhall.

Exiting that fixed cost base and further taking advantage of the slowdown to ramp up our operational efficiency creates a much more durable segment that is better positioned for these cycles in the future. We firmly believe we are creating a healthier and more productive tubular segment and we continue to expect earnings improvements to accelerate over the coming quarters. Turning to our specialty chemicals segment. Ascent Chemicals has experienced general softness across segments. The softness has been compounded further by destocking and working capital corrections in segments such as paints and coatings and personal care as well as select in-sourcing by customers who now find themselves with historically low volumes of internal asset utilization.

Outside of these expectations, we believe our demand has largely been consistent with the softness of the markets we serve. We are currently in the process of raising pricing as a result of our cost escalations. In conjunction with this exercise, we are also working to implement strategies that allow us to adjust pricing more efficiently and quickly to broader macro conditions. I still remain highly confident in this segment and the profitable growth potential we see on the horizon. Having Bryan at the helm has further solidified my confidence and provided our team with a renewed sense of optimism in the future. While we do not forecast material near-term market recovery, our team led by Bryan has been actively working to diversify the markets and customers that we serve while optimizing our cost bases and taking actions to extract the appropriate value for our products and services.

At the end of the day, we feel confident that there are multiple things we can, should and will improve upon that will get us back on track next year. With all of this happening as we speak, we do believe that all these efforts will be accretive to our segment-level adjusted EBITDA as soon as Q1 of 2024. As a whole, our organization is in a much better position today than it has been over the last several quarters. We’re obviously still a good distance from where we want to be but a road map that can get us back there quickly has been developed and we are making tangible progress towards our long-term strategic goals. Although macro volatility doesn’t seem to be letting up in the near future, we will continue to be hammering away at improving our operations and be sure to capitalize on every growth opportunity that comes our way.

We have a strong leader team in place, a more efficient operational footprint and teams within each segment working together much more cohesively. We’re firmly committed to delivering the value that all of our stakeholders have come to expect from us and we look forward to exceeding those expectations in the future. Now, I would like to turn the call over to our CFO, Bill Steckel, who will provide a detailed overview of our third quarter financial results. Then I’ll return to answer any questions you may have. Bill, the floor is yours.

Bill Steckel: Thank you, Chris and good afternoon, everyone. Before I jump into the financials, I want to remind everyone that we have categorized the financial results from our Munhall facility into discontinued operations given that we permanently ceased operations at the end of August. To give a more accurate representation of our performance ex Munhall, the results I’ll be discussing today are from continuing operations and we have adjusted our prior year periods to reflect the results ex Munhall to enable more relevant comparisons. Additionally, I want to update you all on the impact of the Munhall closure on our financials to date. Through the third quarter, we have incurred approximately $2.6 million of pre-tax cash charges and approximately $10.1 million of noncash charges which remain in line with the original expectations.

With that, let’s talk about the third quarter continuing operations. Net sales from continuing operations were $56.1 million compared to $78.2 million in the prior year period. The decrease is due to lower overall sales volume within both tubular products and specialty chemicals segments. Gross profit from continuing operations was $6 million or 10.7% of net sales compared to $14.1 million or 18% of net sales in the third quarter of 2022. The decrease is primarily attributable to the decline in net sales. Net loss from continuing operations was $12.8 million or $1.26 diluted loss per share compared to net income from continuing operations of $3.1 million or $0.30 per diluted share in the third quarter of 2022. The decrease is primarily attributable to an $11.4 million noncash goodwill impairment within the specialty chemicals segment, along with the aforementioned decline in gross profit.

Adjusted EBITDA was $0.9 million compared to $8.2 million in the third quarter of 2022. Adjusted EBITDA margin was 1.7% compared to 10.5% in the prior year period. Lastly, looking at our liquidity position as of September 30, 2023. Total debt was $53 million compared to $71.5 million at December 31, 2022. As of September 30, we had $41.8 million of borrowing capacity under our revolving credit facility compared to $37.6 million at December 31, 2022. During the third quarter of 2023, we repurchased 44,799 shares at an average cost of $8.87 per share for approximately $400,000, bringing total year-to-date purchases for 2023 to nearly 96,000 shares. We currently have 584,024 shares remaining under our share repurchase authorization. With that, I’ll now turn it back over to the operator for Q&A.

Operator: [Operator Instructions] Our first question will come from the line of Vincent Anderson with Stifel.

See also 10 Best European Companies to Invest In and 14 Best Casino Stocks To Buy for 2023.

Q&A Session

Vincent Anderson: So just starting off, I was hoping you could discuss if there are any specific drivers of the goodwill impairment, maybe specifically if that was the loss of a single customer or just a more normal review of the recent operating environment.

Chris Hutter: Yes, it’s pretty much related to the Danville operation and not necessarily the loss of a customer but the normalization of the customers’ go forward estimated annual volume.

Vincent Anderson: Okay. And then sticking to a high level. I know guidance is not on the table. But just looking at your overall level of profitability, how much leverage do you think you have in hand right now from self-help over the next few quarters, if we were to assume no real help in the overall demand environment?

Ben Rosenzweig: I’d say a lot, Vince. I mean we feel pretty good that we can get back to where we were before on the chemical side within the next few quarters without necessarily feeling like there’s going to be a boisterous market environment. Now obviously, I’ll caveat that with — I know it’s pretty bad out there on the chem side and we would hope that it doesn’t get worse. But there are a lot of things under our control that can get us back to where we were before which if you recall, is still not where we think we need to be. So if you were to kind of make that bridge from that mid-single-digit EBITDA margin on the chem side back to where we were in the, call it, 10% range is within our control and then that bridge up to the much higher mid-teens or so, we think, hopefully, there will be a little bit of a normalization in the market and some of these headwinds will abate. But there is a lot within our control.

Vincent Anderson: Okay. Excellent. And then — I’ve got a few. I assume that’s okay. I’m just going to keep going. But can you just maybe discuss at a high — I don’t know if you want to speak for Bryan too soon but at a high level in your chemicals portfolio right now, how you’re thinking about securing new business for volumes lost during this destocking period versus trying to keep the door open for existing relationships. And I don’t want to say counting on the assumption that next year is better but how aggressive are you right now in getting things filled versus maybe managing more of the cost side and just how you go about securing…

Chris Hutter: That’s a great question. I mean we’re doing both. I mean we’re extremely aggressive on the customer touch side. And it’s somewhat difficult or noisy in the numbers but we have facilities. Obviously, our chemical business is 3 facilities. We have certain facilities that are overperforming and certain facilities that are underperforming. So this is — I would say it’s more limited to one facility, the operational struggles right now which we’re addressing and have some light at the end of the tunnel on it. But there’s also a lot of good things and some very good wins we’ve had within other parts of the chemical business that we’re extremely excited about. So after discussing with Bryan, this is — he’s very optimistic about 2024.

Vincent Anderson: Okay. No, that’s good to hear. And that probably answers my next question. But maybe more specifically, you have some larger customers on the chemical side in areas that used to be more predictable revenue streams like agriculture and parts of personal care. I’m curious if they’ve started to offer you guys any kind of color on their planning into next year or if it’s too early to even be counting on those conversations having any weight.

Chris Hutter: I mean we’re having them but I think it’s — they’re — they have cloudiness in their forecast also. So we’re getting — I would say the band of — the range band we have is much wider than normal with the customer volume expectations, whether it be the personal care side and — or even just oil and gas or case. It’s — historically, we’d have — here’s our standard deviation of volume. There will be 1 million to 1.5 million pounds. Now it’s ought to be 500,000 pounds to 2 million pounds. So we’re having those discussions and doing the best we can to also backfill additional demand with other customers.